Reliant Investment Partners LLC Purchases Shares of 342 Axon Enterprise, Inc $AXON

Reliant Investment Partners LLC purchased a new stake in Axon Enterprise, Inc (NASDAQ:AXON) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 342 shares of the biotechnology company’s stock, valued at approximately $283,000.

A number of other hedge funds have also recently made changes to their positions in AXON. TCTC Holdings LLC increased its holdings in Axon Enterprise by 75.0% in the 1st quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 24 shares during the last quarter. Bartlett & CO. Wealth Management LLC grew its stake in shares of Axon Enterprise by 132.0% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 58 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 33 shares in the last quarter. Banque Transatlantique SA acquired a new stake in shares of Axon Enterprise in the first quarter valued at $31,000. Catalyst Capital Advisors LLC purchased a new stake in shares of Axon Enterprise in the 1st quarter valued at $32,000. Finally, Flaharty Asset Management LLC acquired a new position in Axon Enterprise during the 1st quarter worth about $33,000. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Wall Street Analyst Weigh In

AXON has been the subject of several research reports. Bank of America lifted their target price on Axon Enterprise from $895.00 to $1,000.00 and gave the company a “buy” rating in a research report on Wednesday, August 6th. Weiss Ratings restated a “hold (c)” rating on shares of Axon Enterprise in a report on Wednesday, October 8th. Craig Hallum raised shares of Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 target price on the stock in a research note on Tuesday, August 5th. Piper Sandler assumed coverage on shares of Axon Enterprise in a report on Tuesday, September 23rd. They set an “overweight” rating and a $893.00 target price on the stock. Finally, Needham & Company LLC restated a “buy” rating and issued a $870.00 price target on shares of Axon Enterprise in a research note on Wednesday, September 24th. Fourteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, Axon Enterprise has a consensus rating of “Moderate Buy” and an average target price of $841.64.

Axon Enterprise Stock Up 1.8%

Shares of Axon Enterprise stock opened at $749.00 on Tuesday. The company has a quick ratio of 2.71, a current ratio of 2.95 and a debt-to-equity ratio of 0.63. Axon Enterprise, Inc has a 52-week low of $422.38 and a 52-week high of $885.91. The company has a market capitalization of $58.80 billion, a P/E ratio of 184.94, a P/E/G ratio of 28.58 and a beta of 1.41. The company has a 50 day moving average of $732.32 and a 200 day moving average of $727.76.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.58. The business had revenue of $668.54 million for the quarter, compared to analyst estimates of $641.77 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The company’s revenue was up 32.6% on a year-over-year basis. During the same period last year, the business earned $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insider Activity at Axon Enterprise

In other news, CFO Brittany Bagley sold 5,000 shares of the company’s stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $713.88, for a total transaction of $3,569,400.00. Following the completion of the transaction, the chief financial officer directly owned 93,592 shares of the company’s stock, valued at approximately $66,813,456.96. This represents a 5.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Jennifer H. Mak sold 77 shares of the firm’s stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $760.00, for a total value of $58,520.00. Following the sale, the chief accounting officer directly owned 15,003 shares in the company, valued at $11,402,280. This trade represents a 0.51% decrease in their position. The disclosure for this sale can be found here. Insiders sold 59,932 shares of company stock worth $45,115,616 over the last three months. Company insiders own 4.40% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.